<DOC>
	<DOCNO>NCT00482027</DOCNO>
	<brief_summary>The purpose study determine safety immunogenicity ( ability induce immune response ) novel HIV vaccine base adeno-associated virus ( AAV )</brief_summary>
	<brief_title>Safety Immunogenicity Study tgAAC09 , Gag-PR-RT AAV HIV Vaccine</brief_title>
	<detailed_description>The need vaccine prevent AIDS interrupt transmission HIV indisputable . To effective , HIV vaccine induce cellular humoral immune response durable potent . Intra-muscular delivery HIV gene enclose within recombinant adeno-associated virus ( rAAV ) protein capsid show potent inducer antibody T-cell response animal study . tgAAC09 , consist single-stranded DNA Clade C HIV-1 gene gag , protease part reverse transcriptase protein enclose within rAAV serotype 2 protein capsid , develop one component multi-component HIV vaccine . The purpose study evaluate safety immunogenicity tgAAC09 healthy , HIV-seronegative volunteer .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female Age least 18 year day screen great 50 year day vaccination Available followup plan duration study ( screen plus 12 month ) Able give write informed consent ; No report highrisk behavior HIV ( Appendix C ) , willing undergo HIV test receive result ; If sexually active , willing use partner use condom screen least 4 month vaccination . Additional mean contraception permit encourage . Clinically relevant abnormality history examination include history immunodeficiency use immunosuppressive medication last 6 month ; A chronic medical condition concurrent condition , , opinion investigator , would make volunteer unsuitable study . Any following abnormal laboratory parameter mild judge clinically significant principal investigator designee , moderate , severe , severe : hematology ( hemoglobin , absolute neutrophil count [ ANC ] absolute lymphocyte count [ ALC ] , absolute CD4 count , platelet ) ; urinalysis , clinical chemistry ( total bilirubin , creatinine , AST , ALT ) . Refer Appendix D grade laboratory parameter . If female , pregnant planning pregnancy within 4 month receive vaccine , lactate ; Receipt live attenuate vaccine within 60 day vaccine within 14 day vaccination ; Receipt experimental HIV vaccine time ; Receipt blood transfusion blood product within 6 month vaccination ; Participation another clinical trial investigational product currently within 12 week vaccination , expect participation study ; History severe local systemic reaction vaccination history allergic reaction vaccine ; Confirmed infection HIV1 HIV2 ; Positive hepatitis B ( surface antigen ) , hepatitis C antibody , active syphilis ( confirm treponemal test TPHA addition nontreponemal test RPR ) active tuberculosis . Unlikely comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>HIV vaccine</keyword>
	<keyword>Adeno-associated virus vactored vaccine</keyword>
	<keyword>HIV-1 subtype C</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Biodistribution</keyword>
	<keyword>HIV prevention</keyword>
</DOC>